|Day Low/High||25.35 / 26.07|
|52 Wk Low/High||11.50 / 65.24|
This is why I always have some 'dry powder' to deploy during these temporary hiccups.
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
After a strong week for the biotech sector, these names have potential catalysts to move shares.
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
A look at possible second-quarter M&A activity in the biotech sector.
Markets have drifted down since our last update at 11am EST. All major averages are now in the red for the day. Dropbox looks like it will have a strong debut on the market with its IPO 25 times oversubscribed. The biotech sector is slightly up tod...
Your burning biotech questions answered in our latest mailbag.
We'll answer two of the common questions we have received so far in March.
The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.
The market is pretty close to where it was during our last update at noon EST. So far it has been a nicely green day across the board. Oncology mid-cap concern Tesaro is not giving up its big takeover speculation rise yesterday and is up another 3%...
Market are still slightly down across the board as we approach the noon hour. Biotech is hanging in there well despite shellacking Gilead Sciences is taking after ratcheting down guidance. Helping the market is mid-cap concern Tesaro , which is cur...
Animal health and oncology deal activity is heating up in 2017.
The number of new 12-month highs has climbed to 240.
A new treatment has been approved by the FDA for treatment of ovarian cancer. The treatment is made by Clovis Oncology.
Clovis Oncology shares were higher Wednesday after analysts with Credit Suisse boosted the stock's rating to OUTPERFORM from NEUTRAL.
The technical signs indicate the stock's price and volume are going up without a dip.
Wall Street eyes the Fed's decision on interest rates as Mylan's CEO goes to Capital Hill over the EpiPen.
Fundamentals trumped technical analysis in a big way.
Charting setups in Myriad Genetics, Clovis Oncology and Aegerion Pharma.